Vivimed Labs Ltd.

NSE: VIVIMEDLAB  SECTOR: Pharmaceuticals & Drugs

16.5
-0.45 (-2.65%)

Price Summary

Today's High

₹ 17.4

Today's Low

₹ 16.5

52 Week High

₹ 23.62

52 Week Low

₹ 6.5

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.

Company Essentials

Market Cap

136.80795975 Cr.

Enterprise Value

429.54195975 Cr.

No. of Shares

8.2913915 Cr.

P/E

0

P/B

0.26

Face Value

₹ 2

Div. Yield

0%

Book Value (TTM)

₹  62.334

CASH

11.088 Cr.

DEBT

303.822 Cr.

Promoter Holding

32.79%

EPS (TTM)

₹  -1.1839

Sales Growth

9.847979412886%

ROE

-3.64965240725704 %

ROCE

2.66706300554502 %

Profit Growth

-6.930435348474 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

Sales Growth (in Cr.)

1 Year9.85%
3 Year-21.41%
5 Year-8.45%

Profit Growth (in Cr.)

1 Year-409.89%
3 Year-153.34%
5 Year-200.25%

ROE%

1 Year-3.65%
3 Year-0.2%
5 Year5.98%

ROCE %

1 Year2.67%
3 Year4.96%
5 Year8.88%

Debt/Equity

0.5889

Price to Cash Flow

1.82

Interest Cover Ratio

0.52255985267035

CFO/PAT (5 Yr. Avg.)

4.76686775654207

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2020 32.79 60.09
Sep 2020 32.79 60.09
Jun 2020 32.79 60.09
Mar 2020 32.79 63.4
Dec 2019 34.23 66.37
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 27.9501173004296% in the last 5 years.

 Limitations

  • The company has shown a poor profit growth of -153.336252342223% for the Past 3 years.
  • The company has shown a poor revenue growth of -21.4094979551924% for the Past 3 years.
  • Company has a poor ROE of -0.203843015205443% over the past 3 years.
  • Promoter pledging has increased from 32.79% to 60.09% in 1 quarter.
  • Company has a poor ROCE of 4.96460133859597% over the past 3 years
  • Company has low Interest coverage ratio of 0.52255985267035.
  • Promoter pledging is high as 60.09%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020
Net Sales 62.77 55.1 53.53 59.4 62.44
Total Expenditure 52.59 55.11 38.15 46.42 48.72
Operating Profit 10.18 -0.01 15.38 12.98 13.72
Other Income 1.31 1.59 1.36 1.36 1.57
Interest 11.85 10.02 11.4 9.83 11.13
Depreciation 4.17 3.92 3.94 3.95 3.95
Exceptional Items 0 0 0 0 0
Profit Before Tax -4.53 -12.35 1.4 0.55 0.21
Tax 0 -0.61 0.23 0 0
Profit After Tax -4.53 -11.74 1.17 0.55 0.21
Adjusted EPS (Rs) -0.05 -0.14 0.01 0.01 0

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 319.39 569.84 261.39 251.81 276.61
Total Expenditure 232.56 319.35 183.05 184.32 243.87
Operating Profit 86.84 250.49 78.34 67.49 32.73
Other Income 2.79 8.75 1.93 8.54 6.54
Interest 59.49 59.02 53.27 52.63 43.44
Depreciation 18.79 26.83 18.14 18.26 16.57
Exceptional Items 0 0 0 0 0
Profit Before Tax 11.34 173.39 8.85 5.13 -20.74
Tax 3.21 47.04 -1.02 -1.06 -1.57
Net Profit 8.13 126.34 9.87 6.19 -19.17
Adjusted EPS (Rs.) 1 15.59 1.2 0.75 -2.31

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 16.2 16.2 16.51 16.51 16.58
Total Reserves 353.44 544.66 550.9 556.12 537.31
Borrowings 193.03 188.31 115.96 89.71 67.6
Other N/C liabilities 356.96 108.2 172.33 153.7 144.32
Current liabilities 445.75 503.14 399.72 338.52 301.51
Total Liabilities 1365.39 1360.51 1255.41 1154.56 1067.32
Assets
Net Block 386.94 432.93 404.83 380.7 356.42
Capital WIP 40.83 58.64 42.78 64.18 69.77
Investments 230.05 87.6 151.87 87.53 87.5
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 707.57 781.34 655.94 622.14 553.63
Total Assets 1365.39 1360.51 1255.41 1154.56 1067.32
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit Before Tax 11.34 173.39 8.85 5.13 -20.74
Adjustment 37.74 80.21 69.62 62.82 59.57
Working Capital Changes -103.3 -213.96 144.61 40.36 42.23
Tax Paid 0 -11.47 -16.54 -26.26 -6.03
Operating Cash Flow -54.21 28.17 206.55 82.04 75.02
Investing Cash Flow -11.15 29.83 -38.12 56.17 3.32
Financing Cash Flow 58.54 -49.62 -174.8 -123.23 -91.42
Net Cash Flow -6.82 8.38 -6.38 14.98 -13.07

Corporate Actions

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.
Report us

Company News

Vivimed Labs Stock Price Analysis and Quick Research Report. Is Vivimed Labs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Vivimed Labs and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 75.024 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Vivimed Labs has a Debt to Equity ratio of 0.5889 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Vivimed Labs , the EPS growth was -408.434852893631 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Vivimed Labs has OPM of 11.8337997006573 % which is a bad sign for profitability.
     
  • ROE: Vivimed Labs have a poor ROE of -3.64965240725704 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Vivimed Labs

X